AbbVie Receives U.S. FDA Approval of MAVYRET (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks

Press/Media: Press / Media

PeriodAug 3 2017

Media coverage

1

Media coverage

  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletIndia Pharma News
    CountryIndia
    Date8/3/17
    PersonsFred Poordad